ACQUISITION - Narrative (Details) - USD ($)		12 Months Ended
	Jun. 16, 2023	Aug. 31, 2023	Aug. 31, 2022	Aug. 31, 2021
Business Acquisition [Line Items]
Base merger consideration		$ 8,223,000	$ 0	$ 0
Earnout liability		4,780,000
Immunetrics
Business Acquisition [Line Items]
Payments to acquire businesses, gross	$ 13,705,083
Base merger consideration	12,000,000
Earnout liability	8,000,000
Expense fund	$ 250,000
Business acquisition, transaction costs		$ 3,300,000	$ 300,000	$ 0
Acquired finite-lived intangible assets, weighted average useful life	7 years 6 months
Immunetrics | Holdback liability - cash
Business Acquisition [Line Items]
Working capital held back	$ 1,800,000
Immunetrics | Earnout liability - cash
Business Acquisition [Line Items]
Earnout liability	$ 8,000,000